Grifols has been granted a patent for a method using benzodioxane inhibitors to prevent and treat aging-associated diseases like cognitive disorders. The method involves administering a compound to improve cognitive function in subjects with age-related cognitive diseases. GlobalData’s report on Grifols gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Grifols, Attenuated virus-based vaccines was a key innovation area identified from patents. Grifols's grant share as of May 2024 was 50%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of aging-associated diseases using benzodioxane inhibitors
A recently granted patent (Publication Number: US11957671B2) discloses a method for improving cognitive function in individuals diagnosed with age-related cognitive diseases. The method involves administering a therapeutically effective amount of a compound of formula (I), which includes a wide range of specific compounds. These compounds are selected from various groups, such as benzodioxin-2-yl benzyl derivatives, piperidines, morpholines, and other complex structures. The compounds are designed to target cognitive function improvement in subjects with age-related cognitive diseases like CADASIL.
The patent claims specify the structure and composition of the compounds, including the presence of non-aromatic monocyclic radicals, spirocyclic heterocyclic radicals, and bridged bicyclic or fused bicyclic radicals. The compounds may also contain various substituents, such as halo, hydroxyl, carbonyl, and alkyl groups. Additionally, the patent outlines the specific configurations of the compounds, including the presence or absence of certain linkers and functional groups. The method aims to address cognitive decline associated with age-related cognitive diseases by targeting specific molecular structures with therapeutic compounds of formula (I), potentially offering new treatment options for individuals with conditions like CADASIL.
To know more about GlobalData’s detailed insights on Grifols, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
